Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 364

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Aspirin Plus Heparin or Aspirin Alone in Women With Recurrent Miscarriage

Kaandorp, Stef P., Goddijn, Mariëtte, van der Post, Joris A. M., Hutten, Barbara A., Verhoeve, Harold R., Hamulyák, Karly, Willem Mol, Ben, Folkeringa, Nienke, Nahuis, Marleen, Papatsonis, Dimitri N. M., Büller, Harry R., van der Veen, Fulco, Middeldorp, Saskia · 2010 · Obstetrical & Gynecological Survey

Abstract

Despite intensive investigation, an underlying cause of miscarriage has not been found in a high proportion of women with a history of recurrent miscarriage. No effective intervention has been identified that improves rates of live birth. Some investigators have suggested that treatment of women with unexplained recurrent miscarriage with aspirin and low-molecular-weight heparin may increase the proportion of live births; the limited data available from randomized controlled trials have been inconsistent. This multicenter, randomized, placebo-controlled trial investigated whether a combination of aspirin with low-molecular-weight heparin or aspirin alone, compared with placebo, would improve the live-birth rate in women with a history of unexplained recurrent miscarriage. The study subjects were 364 women aged 18 to 42 years with a history of unexplained recurrent miscarriage who were trying to conceive or were pregnant less than 6 weeks. Women were randomly assigned to receive combined therapy (n = 123) consisting of daily doses of aspirin 80 mg plus open-label subcutaneous low-molecular-weight heparin (nadroparin) at a dose of 2850 IU, or 80 mg of aspirin alone (n = 120), or placebo (n = 121) either before conception or at a gestational age of less than 6 weeks. The main study outcome measure was the rate of live birth. Secondary outcome measures included rates of miscarriage, obstetrical complications, and maternal and neonatal adverse events. No significant difference between the 3 study groups was found in the proportion of live births (combined therapy, 54.5%; aspirin only, 50.8%; and placebo, 57%); the absolute difference in live-birth rate for combined therapy versus placebo was −2.6 percentage points, with a 95% confidence interval of −15.0 to 9.9; and for the aspirin only versus placebo was −6.2, with a 95% confidence interval of −18.8 to 6.4 (P = 0.63). There was also no significant difference in the live-birth rates among the 299 women in these 3 groups who became pregnant; the rates were 69.1% in the combined therapy group, 61.6% in the aspirin-only group, and 67.0% in the placebo group (P = 0.52). Compared to the other 2 groups, the combined therapy group had a significantly increased tendency for bruising and swelling or itching at the injection site (P < 0.001). These findings demonstrate that neither aspirin combined with nadroparin nor aspirin alone increase the likelihood of a live birth in comparison with placebo among women with unexplained recurrent miscarriage.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/ogx.0b013e3182021f71

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 364

Metadata

Authors
Kaandorp, S. P., Goddijn, M., van der Post, J. A. M., Hutten, B. A., Verhoeve, H. R., Hamulyák, K., Willem Mol, B., Folkeringa, N., Nahuis, M., Papatsonis, D. N. M., Büller, H. R., van der Veen, F., & Middeldorp, S.
Venue
Obstetrical & Gynecological Survey
Published
2010-10
Volume
65
Issue
10
Pages
621-622
ISSN
0029-7828 (ISSN-L)
OpenAlex
W4231905096
Cited by
364
References
4
FWCI
15.22
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Aspirin Plus Heparin or Aspirin Alone in Women With Recurrent Miscarriage. https://app.cochat.ai/papers/10.1097/ogx.0b013e3182021f71
The paper
Kaandorp, S. P., Goddijn, M., van der Post, J. A. M., Hutten, B. A., Verhoeve, H. R., Hamulyák, K., Willem Mol, B., Folkeringa, N., Nahuis, M., Papatsonis, D. N. M., Büller, H. R., van der Veen, F., & Middeldorp, S. (2010). Aspirin Plus Heparin or Aspirin Alone in Women With Recurrent Miscarriage. Obstetrical & Gynecological Survey. https://doi.org/10.1097/ogx.0b013e3182021f71

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.